Announcements
- Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer
- Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
- Information on the total number of voting rights and shares
- Informations sur le nombre total de droits de vote et d'actions
- Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation
- Nyxoah Fait Progresser sa Stratégie d'Accès aux Patients en Annonçant un Partenariat Stratégique avec l'American Association of Otolaryngology – Head & Neck Surgery Foundation
- Nyxoah Annonce que l'Étude Pivot DREAM U.S. Atteint les Critères d'Évaluation Primaires
- Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
- Nyxoah Publie ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Exercice 2023
- Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
More ▼
Key statistics
On Friday, Nyxoah SA (5YI:FRA) closed at 8.92, 146.41% above the 52 week low of 3.62 set on Jan 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.72 |
---|---|
High | 8.92 |
Low | 8.58 |
Bid | 8.94 |
Offer | 9.88 |
Previous close | 8.78 |
Average volume | 0.00 |
---|---|
Shares outstanding | 28.66m |
Free float | 14.55m |
P/E (TTM) | -- |
Market cap | 269.42m EUR |
EPS (TTM) | -1.55 EUR |
Data delayed at least 15 minutes, as of May 03 2024 14:29 BST.
More ▼